AIbase Report With the deep penetration of artificial intelligence in the medical field, 2025 has become a key year for the explosive growth of AI in healthcare. The latest financing updates from the overseas medical AI platform OpenEvidence have drawn widespread attention in the industry, while Ant Group, a domestic giant, launched an upgraded health AI product at the same time, further demonstrating the broad prospects of AI in healthcare.

OpenEvidence's valuation surges to $12 billion

According to reliable sources, the AI platform OpenEvidence, which focuses on physician clinical decision support, is currently conducting a new round of financing, planning to raise about $250 million with a valuation of $12 billion. This is just a few months after its previous round of financing, and the valuation has doubled.

OpenEvidence is known as the "doctor's专属 ChatGPT," and its core product is a medical Q&A and evidence retrieval system designed specifically for doctors and clinical staff:

- Quickly provide credible medical evidence, with all conclusions traceable to real peer-reviewed literature;

- Directly applicable to real clinical decision-making scenarios, supporting point-of-care rapid queries;

- Completely free for registered doctors, primarily generating revenue through pharmaceutical advertising and content collaboration with medical partners.

Recent data show that the platform's annual ad revenue has reached $150 million, tripling since August, with a gross profit margin of over 90%. It now covers more than 40% of physicians in the United States, processing millions of clinical consultations each month and highly favored by healthcare institutions.

Financing history review

Since its establishment, OpenEvidence has had a fast financing pace:

- February 2025: A round financing of about $75 million, valuation of about $1 billion;

- July 2025: B round financing of about $210 million, valuation of about $3.5 billion;

- October 2025: C round financing of about $200 million, valuation of about $6 billion;

- Latest round: Expected $250 million, valuation of $12 billion.

This valuation jump reflects investors' high confidence in vertical AI medical applications, especially the unique advantages in evidence-based medical support.

Domestic updates: Ant Group launches "Ant Afu"

At the same time, another major news has emerged in the domestic AI healthcare sector. Ant Group officially renamed its AI health application AQ to "Ant Afu" and released a new version, marking a comprehensive transformation of the product positioning from an "AI diagnosis tool" to "daily health companionship."

The upgraded "Ant Afu" focuses on the "Health+" strategy, with three core functions fully optimized:

- Health companionship: Connects to smartwatches and other devices, consolidates user exercise, sleep, medical history, and consultation data, establishes personal and family health records, and realizes AI "personal companionship" management;

- Health Q&A: Provides professional and accurate multimodal interaction, supporting personalized advice tailored to individuals;

- Health services: Integrates practical features such as appointment registration and cloud companion care.

Currently, "Ant Afu" has over 15 million monthly active users, becoming the largest AI health management application in China, answering over 5 million health questions daily, and performing well in the lower-tier markets. The product relies on a professional medical large model, emphasizing reliability and inclusiveness, and has already formed a significant leading advantage in the AI health field.

The future of AI healthcare is promising